OUR DEVELOPMENT PORTFOLIO
Updated April 2021
-
Oncology -
Cardiometabolism -
Neuroscience -
immuno-inflammation
Phase 1
Haematological malignancies
Mcl1 inhibitor
Haematological malignancies
Bcl2 inhibitor
Haematological malignancies
UCART 19
Haematological malignancies
Cart 19
Solid tumors
Anti PD1xAnti TIM3
Solid tumors
Anti CD73
Solid tumors
AG270
Relapsed or refractory myelodysplastic syndrome (MDS)
Tibsovo (pre-registration)
Phase 2
Colorectal cancer
Anti EGFR
Lung cancer
Anti cMET
Sjögren disease / Crohn's disease
Anti IL7R
Phase 3
Colorectal cancer, 1st line Combo
Lonsurf
Colorectal cancer, 3rd line Combo
Lonsurf
Autism
Bumetanide
Acute myeloid leukemia (AML) IC-ineligible, 1st line
Tibsovo
Acute myeloid leukemia (AML) IC-eligible, 1st line
Tibsovo
Cholangiocarcinoma
Tibsovo
Low-grade Glioma
Vorasidenib